SCHEMBL348938

SCHEMBL348938

CCC(C(=O)O)c1ccc(NC(=O)O[C@H](C)OC(=O)C(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 3/20 0.47
CRHR2 Q13324 3/20 0.47
SMN1; SMN2 Q16637 4/20 0.44
HPGD P15428 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 2/20 0.42
RECQL P46063 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
AKR1C3 P42330 3/20 0.39
AKR1C2 P52895 3/20 0.39
AKR1C1 Q04828 1/20 0.39
PTGS1 P23219 1/20 0.39
HDAC3 O15379 3/20 0.39
HDAC4 P56524 3/20 0.39
HDAC1 Q13547 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL351083 1.00 CRHBP (0.47) CRHBPCRHR2SMN1; SMN2HPGDNPC1
SCHEMBL349357 0.88 CRHBP (0.45) CRHBPCRHR2SMN1; SMN2HPGDNPC1
SCHEMBL351928 0.88 CRHBP (0.45) CRHBPCRHR2SMN1; SMN2HPGDNPC1
SCHEMBL348939 0.81 FFAR1 (0.43) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
SCHEMBL351084 0.81 FFAR1 (0.43) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
SCHEMBL350646 0.78 SMN1; SMN2 (0.42) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
SCHEMBL1877214 0.76 CYP17A1 (0.53) CRHBPCRHR2ALDH1A1AKR1C3AKR1C2
SCHEMBL31357785 0.74 CRHBP (0.55) CRHBPCRHR2SMN1; SMN2HPGDNPC1
SCHEMBL358839 0.74 HPGD (0.43) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
SCHEMBL261231 0.73 KIF11 (0.54) CRHBPCRHR2SMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016021-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS XENOPORT, INC. (US) 2012-01-19 US claimed
US-20120016021-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS XENOPORT, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016021-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS GABBR2, GABBR1, GABRB1 CRHBP 1820/4885CRHR2 358/4885SMN1; SMN2 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.